Search
ischemic cardiomyopathy
Etiology:
- myocardial ischemia
- myocardial infarction
Pathology:
- heart failure
Management:
- also see ischemic heart disease & dilated cardiomyopathy
- CABG significantly outperforms medical therapy for all-cause mortality (59 vs 66% over 9.8 years) [2]
- myocardial viability does not predict benefit from revascularization or mortality [3]
- no benefit to percutaneous coronary intervention [4]
- stem cell therapy is investigational
- older age does not diminish improvements after stem cell therapy [1]
General
ischemic heart disease (IHD)
dilated cardiomyopathy
References
- Golpanian S et al.
Effect of aging on human mesenchymal stem cell therapy in
ischemic cardiomyopathy patients.
J Am Coll Cardiol 2015 Jan 20; 65:125
PMID: 25593053
http://www.sciencedirect.com/science/article/pii/S0735109714069496
- Velazquez EJ et al.
Coronary-artery bypass surgery in patients with ischemic
cardiomyopathy.
N Engl J Med 2016 Apr 3;
PMID: 27040723
http://www.nejm.org/doi/10.1056/NEJMoa1602001
- Guyton RA, Smith AL.
Coronary bypass - Survival benefit in heart failure.
N Engl J Med 2016 Apr 3
PMID: 27040599
http://www.nejm.org/doi/10.1056/NEJMe1603615
- Panza JA, Ellis AM, Al-Khalidi HR et al.
Myocardial viability and long-term outcomes in ischemic cardiomyopathy.
N Engl J Med 2019 Aug 22; 381:739
PMID: 31433921
https://www.nejm.org/doi/10.1056/NEJMoa1807365
- Perera D et al.
Percutaneous revascularization for ischemic left ventricular dysfunction.
N Engl J Med 2022 Aug 27; [e-pub].
PMID: 36027563
https://www.nejm.org/doi/10.1056/NEJMoa2206606